Clinical trials: Previously Treated Non-Small Cell Lung Cancer
- Condition Previously Treated Non-Small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
Non-small Cell Lung Cancer
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.
- Trial name
- NCT01465243
- Testing
- Icotinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs.
- Trial name
- NCT07459751
- Testing
- HLX43, HLX43+HLX07, Docetaxel
- Where
- China
- Volunteers
- 706 people
- Sponsor
- Shanghai Henlius Biotech
NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer)
A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
This study evaluated the safety and tolerability of epacadostat (INCB024360) administered in combination with atezolizumab (MPDL3280A) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that were…
- Trial name
- NCT02298153
- Testing
- Epacadostat, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Incyte Corporation
Lung Cancer
BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BBR 3464 in treating patients who have metastatic small…
- Trial name
- NCT00014547
- Testing
- BBR 3464
- Where
- 18 sites in United States
- Sponsor
- Theradex
Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol.
- Trial name
- NCT00033722
- Testing
- folic acid, lometrexol
- Where
- 7 sites in United States
- Sponsor
- Tularik
Non-small Cell Lung Cancer
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
- Trial name
- NCT00372073
- Testing
- seliciclib
- Where
- 20 sites in United States
- Volunteers
- 187 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer, Leptomeningeal Metastases
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or…
- Conditions
- Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
- Trial name
- NCT02616393
- Testing
- Tesevatinib
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Kadmon Corporation, LLC
Non-Small Cell Lung Cancer
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment
- Trial name
- AGA TKI NSCLC (NCT07158840)
- Testing
- AK112
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso
Non Small Cell Lung Cancer
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib
- Trial name
- NCT00743938
- Testing
- BMS-690514, Erlotinib
- Where
- 30 sites in United States, Argentina and 6 more
- Volunteers
- 141 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy.
- Trial name
- NCT00457119
- Testing
- RAD001
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
- Trial name
- NCT04303780
- Testing
- AMG 510, Docetaxel
- Where
- 274 sites in United States, Australia and 21 more
- Volunteers
- 345 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
- Trial name
- FORTIS-M (NCT00707304)
- Testing
- Talactoferrin
- Where
- 189 sites in United States, Australia and 21 more
- Volunteers
- 742 people
- Sponsor
- Agennix
Non-Small Cell Lung Cancer
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd continued until the patient experienced unacceptable toxicity that precluded further treatment, discontinued treatment at the discretion of…
- Trial name
- NCT01685060
- Testing
- LDK378
- Where
- 52 sites in United States, Canada and 10 more
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Nonsmall Cell
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
Patient selection: a) Pathological confirmation of non-small cell lung cancer without activating EGFR mutations; b) Advanced stage disease (IV or IIIB with malignant effusion) with at least two prior chemotherapy regimens; c) No…
- Trial name
- NCT02991651
- Testing
- IRX4204, erlotinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Io Therapeutics
MTAP-deleted NSCLC
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
- Trial name
- NCT06593522
- Testing
- anvumetostat
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 61 people
- Sponsor
- Amgen
Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no…
- Trial name
- NCT05555732
- Testing
- Datopotamab Deruxtecan, Pembrolizumab, Pemetrexed
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 1,170 people
- Sponsor
- Daiichi Sankyo
Non-small Cell Lung Cancer
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic…
- Trial name
- NCT04656652
- Testing
- DS-1062a, Docetaxel
- Where
- 209 sites in United States, Argentina and 24 more
- Volunteers
- 605 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.
- Trial name
- NCT03381274
- Testing
- Oleclumab, Osimertinib, AZD4635
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 43 people
- Sponsor
- MedImmune LLC
NSCLC (Advanced Non-small Cell Lung Cancer)
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer…
- Trial name
- EMPATHY NSCLC (NCT07096258)
- Where
- 4 sites in France, Italy and 2 more
- Volunteers
- 1,000 people
- Sponsor
- Hedera Dx SA